VIVS earnings analysis
What we found in VIVS's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
VivoSim remains an early-stage, loss-making biotechnology services company, reporting approximately $40,000 of revenue and negative $2.21 EPS for the period. Liquidity improved through a $5.0 million Eli Lilly milestone and financing-related actions, and Nasdaq equity compliance was regained on August 4, 2026, but management continues to identify substantial doubt about going-concern status, with $2.8 million of quarterly operating losses and a $357.3 million accumulated deficit. Funding needs, potential dilution from 10,082,405 warrant shares, and ongoing Nasdaq MVLS risk remain material negatives.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- $5.0M Eli Lilly milestone received
- The company received a $5.0 million milestone payment from Eli Lilly in July 2026 related to the FXR314 asset sale, although future milestone payments remain uncertain.
- Nasdaq equity compliance regained
- Nasdaq confirmed on August 4, 2026 that the company regained compliance with Listing Rule 5550(b)(1), which requires at least $2.5 million of stockholders’ equity.
- Positive $1.3M working capital
- As of June 30, 2026, current assets were approximately $3.2 million versus current liabilities of approximately $1.9 million, producing working capital of $1.3 million.
- Revenue remains minimal
- The company reported quarterly revenue of approximately $40,000 and EPS of negative $2.21, reflecting a highly limited revenue base and continued losses.
- Stock traded between $1.03 and $1.71
- The company’s closing stock price ranged from $1.03 to $1.71 during the quarter ended June 30, 2026, highlighting continued market volatility.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Going-concern uncertainty
- Management concluded that substantial doubt exists about the company’s ability to continue as a going concern. Operating losses were $2.8 million for the three months ended June 30, 2026, and accumulated deficit was $357.3 million.
- Additional funding and dilution
- The company states that it does not expect to generate meaningful revenue in the foreseeable future and may need substantial additional funding. It has capacity to sell up to $3.1 million of additional common stock through its ATM facility, creating potential dilution.
- Nasdaq MVLS delisting risk
- Although equity compliance was regained, Nasdaq’s proposed $5.0 million Market Value of Listed Securities requirement could result in immediate suspension and delisting after 30 consecutive business days below the threshold if the rule takes effect; the SEC approval is currently stayed.
- Large warrant overhang
- As of August 10, 2026, the company had 25,285,144 common shares issued and outstanding or available on a fully diluted basis, including 10,082,405 shares issuable upon warrant exercise.
- Persistent operating losses
- The company reported $2.8 million of operating losses for the quarter ended June 30, 2026, compared with $2.9 million in the prior-year quarter, and expects substantial additional operating losses over the next several years.
- Future milestone payments uncertain
- The $5.0 million milestone received in July 2026 was tied to one development milestone; the FXR Asset Sale permits potential milestone payments of up to $50.0 million in aggregate, but there is no assurance that additional milestones will be achieved or paid.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-2.21
What they said about what is next.
No quantitative revenue or EPS guidance was provided in the filing; outlook was deferred/not provided.
The filing reads worse than the one before it.
What came before.
- 10-K · July 14, 2026
- VivoSim Labs, Inc.'s 10-K filing for the fiscal year ending March 31, 2026, highlights the company's shift to providing testing services using 3D human tissue models, anticipating growth in this area following FDA…
- 10-Q · February 11, 2026
- VivoSim Labs reported $26,000 of revenue for the quarter ended December 31, 2025 (up from $24,000 a year ago) and a narrower GAAP net loss per share of $(1.03) versus $(2.28) in the prior-year quarter. Operating losses…
- 10-Q · November 6, 2025
- VivoSim Labs reported quarterly revenue of $28,000 (royalties) and a GAAP net loss per share of $(0.98), an improvement from $(1.68) in the prior-year quarter. Cash and cash equivalents declined to $6.677 million from…
- 10-Q · November 8, 2024
- Organovo reported Q2 revenue of $30,000 (royalties $28,000; product/Mosaic $2,000) and a narrower net loss of $2,549,000 (EPS -$0.14) versus a net loss of $3,994,000 (EPS -$0.46) in the prior-year quarter. Operating…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing VIVS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever